Insulet initiated with a Peer Perform at Wolfe Research

Wolfe Research analyst Mike Polark initiated coverage of Insulet with a Peer Perform rating and $280-$335 fair value range. The Omnipod 5 launch is a "material volume catalyst" in 2023 and beyond, but Insulet’s profitability and cash flow "underwhelm" and driving leverage does not appear a near-term priority, the analyst tells investors in a research note.